EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Molecular mechanisms and biomarkers in glioma: recent advances and future perspectives

Yongguang Zhang, Yushan Chen, Shisiyu Zheng, Miaohui Huang, Jiawei Hu, Yuhuang Xu, Xuqiao Mei, Weiwei Wang, Xiao Yang

Neurosurgical Review · 14.11.2026 · 49 (1)

DOI: 10.1007/s10143-026-04569-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurosurgical Review, online erschienen am 14.11.2026. Verfasst von Yongguang Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Center, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China. Hauptthemen laut MEDLINE: Glioma, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 108 Literaturangaben. Gefördert von: Zhangzhou Science and Technology Plan Projects, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas are the most common primary tumors of the central nervous system, with high heterogeneity and aggressiveness. Recent advances have elucidated key molecular mechanisms in glioma pathogenesis, including dysregulation of the RTK/RAS/PI3K, p53, and RB pathways, alongside significant epigenetic alterations like IDH mutations and MGMT promoter methylation in tumorigenesis. In addition, biomarkers including 1p/19q codeletion and TERT promoter mutations have been incorporated into clinical trials to guide prognostic assessment and treatment decisions. IDH mutation status has additionally emerged as a predictive biomarker with direct therapeutic consequences, exemplified by the regulatory approval of vorasidenib for IDH-mutant grade 2 glioma. Furthermore, non-invasive liquid biopsy techniques, such as analysis of cerebrospinal fluid (CSF)-derived circulating tumor DNA and exosomes, have emerged as promising tools for dynamic surveillance and early tumor detection. This review summarizes the progress of research into the molecular mechanisms of glioma, discusses potential diagnostic and therapeutic biomarkers, and looks ahead to future research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBiomarkers, TumorBrain NeoplasmsHumansIsocitrate DehydrogenaseMutation

Stichwörter der Autor:innen

BiomarkerCSFGliomaIDHLiquid biopsyRTK

Substanzen

Biomarkers, TumorIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Precision Medicine Center, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
  • Department of Imaging, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
  • Department of Reproductive Medicine, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
  • Department of Clinical Laboratory, Chaoyang Hospital of Zhangzhou City, Zhangzhou, China.
  • Precision Medicine Center, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China. qianyimei@126.com.
  • Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China. 598038509@qq.com.

Förderung

  • Zhangzhou Science and Technology Plan Projects
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, Y., Chen, Y., Zheng, S., Huang, M., Hu, J., Xu, Y., Mei, X., Wang, W., & Yang, X. (2026). Molecular mechanisms and biomarkers in glioma: recent advances and future perspectives. Neurosurgical Review, 49(1). https://doi.org/10.1007/s10143-026-04569-3

Vancouver

Zhang Y, Chen Y, Zheng S, Huang M, Hu J, Xu Y, et al. Molecular mechanisms and biomarkers in glioma: recent advances and future perspectives. Neurosurgical Review. 2026;49(1). doi:10.1007/s10143-026-04569-3

BibTeX
@article{Zhang2026,
  author = {Zhang, Yongguang and Chen, Yushan and Zheng, Shisiyu and Huang, Miaohui and Hu, Jiawei and Xu, Yuhuang and Mei, Xuqiao and Wang, Weiwei and Yang, Xiao},
  title = {Molecular mechanisms and biomarkers in glioma: recent advances and future perspectives},
  journal = {Neurosurgical Review},
  year = {2026},
  volume = {49},
  number = {1},
  doi = {10.1007/s10143-026-04569-3}
}
Kostenlos starten →